Smart drug delivery technologies for Inflammatory Bowel Diseases (IBD) focus on site-specific therapeutic delivery, enhancing treatment efficacy while minimizing side effects. Recent advancements, including ingestible smart capsules, offer precise targeting within the gastrointestinal (GI) tract. Despite previous commercialization challenges, progress in technology, miniaturization, and component design has reignited interest. Smart capsules, equipped with drug reservoirs, sensors, and localization mechanisms, promise improved treatment for IBD by accurately releasing drugs at disease sites, overcoming limitations of traditional drug delivery methods.
Trending
- SAGA Diagnostics® Launches Ultrasensitive Pathlight™ MRD Test in Colorectal Cancer (Business Wire)
- Task force updates ERCP quality metrics (GI & Hepatology News)
- New simulator mimics real tissue for safer endoscopic cancer surgery training (Medical Xpress)
- 5 GI leaders on what’s changing in colonoscopy (Becker’s GI & Endoscopy)
- Scientists create a luminous pill with biosensors meant to replace colonoscopies (Earth.com)
- FUJIFILM 800 Series Duodenoscopes Now Compatible with CE Mark Approved ULTRA GI Cycle (Fujifilm)
- Private Equity’s Healthcare Boom Is Getting More Crowded (MedCity News)
- Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab (Reuters)
